血栓性血栓塞性紫外线:在中风预防指南中错过的原因
Adrien Picod1,2, Bérangère S Joly2,3,4, Agnès Veyradier2,3,4
1Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France (A.P.).
Stroke
|March 7, 2025
概括
"2024年中风预防指南"没有为血栓性血栓细胞缩紫外线患者提供关键建议. 包括具体的建议和ADAMTS13测试可以预防这一脆弱群体中风.
科学领域:
- 神经学 神经学
- 血液学 血液学 血液学
- 心血管医学 心血管医学
背景情况:
- "2024年初级预防中风指南"强调了脑血管疾病的可修改风险因素.
- 目前的指导方针涉及高血压,糖尿病,动脉样硬化疾病和遗传性中风倾向.
- 血栓性血栓塞性紫外线 (TTP) 患者面临高风险的中风,往往是其主要表现.
研究的目的:
- 为了确定2024年中风预防指南中的遗漏.
- 倡导包括针对TTP患者的具体建议.
- 强调ADAMTS13活动测量在密码性中风处理中的重要性.
主要方法:
- 审查2024年美国心脏协会/美国中风协会中风预防指南.
- 分析了TTP和缺血性中风之间的确立联系.
- 对与TTP相关的血栓事件的潜在预防性干预措施的评估.
主要成果:
- 2024年的指导方针缺乏针对血栓性血栓细胞缩性紫外线患者的具体建议.
- 脑卒中是一个显著的风险和TTP的潜在唯一表现.
- 建议使用ADAMTS13活动测试进行密码性中风评估.
结论:
- 未来的中风预防指南必须包括针对TTP患者的具体建议.
- 早期发现和治疗TTP对于预防中风至关重要.
- 考虑ADAMTS13测试可以帮助诊断TTP患者中风的原因.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
588
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
588
Disorders of Hemostasis
676
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
676
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
448
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
448
Clot Retraction and Fibrinolysis
3.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.2K


